STAAR Surgical Company's stock surged 12.28% in post-market trading on Wednesday, following the release of its first-quarter 2026 financial results that significantly exceeded market expectations.

The intraocular lens maker reported a return to profitability with Q1 earnings of $0.10 per diluted share, beating the consensus estimate which anticipated a loss. Revenue more than doubled year-over-year to a record $93.5 million, well above analyst forecasts. The company attributed the strong performance primarily to a recovery in demand in China, normalization of distributor inventory, and the successful launch of its EVO+ ICL product in the region.

Gross margin improved substantially to 73.6% from 65.8% a year earlier, driven by manufacturing efficiencies and lower costs. Management expressed confidence in consistent, profitable growth for 2026, with plans for its Swiss facility to supply all lenses shipped to China, thereby avoiding import tariffs.